Provide feedbackProvide feedback
Home :: Neurosurgery

Deep brain stimulation shows greater efficacy than best medical care in advanced PD; associated with higher adverse event rates, trial data show

Wednesday, January 21 2009 | Comments
Evidence Grade 1 What's This?

Relative to optimal medical therapy, deep brain stimulation (DBS) extends "on" time and improves motor function and quality of life (QOL) in patients with advanced Parkinson's disease (PD), data from a randomized trial indicate. However, the study findings also reveal a higher rate of adverse events with the surgical intervention. Researchers randomized 255 patients with PD (Hoehn and Yahr stage >=2 when off medication) to receive best medical therapy managed by movement disorder...

Relative to optimal medical therapy, deep brain stimulation (DBS) extends "on" time and improves motor function and quality of life (QOL) in patients with advanced Parkinson's disease (PD), data from a randomized trial indicate. However, the study findings also reveal a higher rate of adverse events with the surgical intervention.

Researchers randomized 255 patients with PD (Hoehn and Yahr stage >=2 when off medication) to receive best medical therapy managed by movement disorder neurologists (n=134), or DBS of the subthalamic nucleus (n=60) or globus pallidus (n=61).

The intent-to-treat analysis of the primary outcome measure showed that after 6 months of treatment, the DBS group had gained an average of 4.6 hours per day of on time without troubling dyskinesias, compared with 0 hours per day gained in the medical therapy group (between-group mean difference, 4.5 hr/day; 95% CI, 3.7-5.4 hr/d; P<.001).

Results also showed significantly greater improvements with DBS in Unified Parkinson's Disease Rating Scale off-medication motor scores, activities of daily living scores, and complications of therapy scores (P<.001 for all comparisons). In addition, DBS was associated with significantly greater improvements in QOL (P<.001 for between-group difference in overall QOL score).

There were small but statistically significant declines in some cognitive test scores with DBS compared with best medical therapy. Between-group differences were significant for working memory (P=.005), processing speed (P=.006), phonemic fluency (P<.001), and delayed recall (P=.03).

A total of 659 moderate or severe adverse events were documented in the DBS group, compared with 236 such events in the best-medical-therapy group. DBS was associated with significantly higher rates of falls (P<.01), gait disturbances (P=.03), depression (P=.03), and dystonia (P<.01). Other adverse events with DBS included surgical site infection (9.9%) and surgical site pain (9.0%).

The most common neurobehavioral adverse events were depression, confusional state, and anxiety, all of which were more common with DBS than with best medical therapy.

A total 82 serious adverse events (SAEs) occurred in 49 of the DBS-treated patients (40%), including 39 events related to the surgical procedure and 1 death following a cerebral hemorrhage 24 hours after lead implantation. Significantly fewer patients experienced an SAE in the best-medical-therapy group (19 events in 15 patients; 11%; P<.001). The overall incidence risk of experiencing an SAE was 3.8 times higher with DBS than with best medical therapy (95% CI, 2.3-6.3).

In general, the authors noted, the benefits of DBS relative to best medical therapy were similar in younger (aged <70 years) and older patients. However, they added, while the incidence of SAEs did not differ by age, adverse events in general were more common in the older age group.

"The clinical significance of the adverse events and minor neurocognitive changes observed in patients in the DBS group and, more importantly, whether patients who undergo DBS view improvement in motor function and QOL as outweighing adverse events, remain to be explored," the investigators concluded. (Weaver FM, et al. JAMA 2009;301:63-73.)

Medtronic Neuromodulation provided financial support for this study.

Latest News

Researchers find similar case-fatality rates among patients with intracerebral hemorrhage in 1988, 2005; more trials warranted to improve ICH outcomes Verusmed

Tuesday, December 16 2008 | Comments
Evidence Grade 1 What's This?

The frequency of surgery for intracerebral hemorrhage (ICH) was lower in 2005 than in 1988, according to a recently published study, but the overall ICH case-fatality rate was not improved in 2005 compared with 1988, suggesting the need for innovative therapies and clinical trials in the care of ICH.

The study investigators said the decreased use of surgery to treat ICH could reflect the impact of recent clinical trial data that demonstrate no clear benefit to surgery relative...



Repeat Gamma Knife radiosurgery relieves pain in majority of patients with trigeminal neuralgia, long-term data indicate Verusmed

Tuesday, December 16 2008 | Comments
Evidence Grade 3 What's This?

Repeat Gamma Knife radiosurgery (GKRS) relieves pain in more than two-thirds of patients with trigeminal neuralgia, according to long-term follow-up data, although additional studies are needed to determine an optimized treatment protocol.

Researchers evaluated 93 patients with trigeminal neuralgia who underwent stereotactic radiosurgery at the Medical University of Graz in Austria between 1994 and 2006. Of these patients, 22...



Researchers call for new strategies to diagnose, prevent asymptomatic infarction from vasospasm in patients with poor-grade subarachnoid hemorrhage Verusmed

Monday, December 15 2008 | Comments
Evidence Grade 1 What's This?

New approaches are needed to diagnose and prevent asymptomatic infarction in patients with subarachnoid hemorrhage (SAH), according to the authors of a study conducted at the Columbia University Medical Center.

The researchers noted that delayed cerebral ischemia (DCI) resulting from vasospasm contributes significantly to poor outcomes in this population and that diagnosing DCI can be especially difficult in patients with depressed...



Surgery seems more beneficial than continued drug treatment in eligible patients with pharmacoresistant epilepsy, analysis suggests Verusmed

Monday, December 15 2008 | Comments
Evidence Grade 1 What's This?

A new decision analysis model indicates that anterior temporal lobe resection would generally provide substantial life expectancy improvements relative to medication therapy in surgically eligible patients with pharmacoresistant temporal lobe epilepsy.

The study authors explained that epilepsy surgery is underused, even though as many as 40% of patients with epilepsy are refractory to antiepileptic drugs. A randomized trial to evaluate the 2 treatments would be unlikely, so...

Tags: Epilepsy




  1. No articles have been read
  1. No articles have been emailed
Videos